Cure My Disease

Don't miss your cure!

 Log in / Sign up

New stent aims to tackle tough heart blockages

NCT ID NCT07491107

Not yet recruiting Disease control Sponsor: Scitech Produtos Medicos SA Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This registry will follow 2000 people with complex coronary artery disease who receive the Inspiron EVO drug-eluting stent. The stent is designed to be easier to deliver and stronger than standard stents. Researchers will track how well the stent works and whether it reduces heart attacks, death, or the need for repeat procedures.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Inspiron EVO Drug-Eluting Stent
What this could lead to
If successful, this could show that the Inspiron EVO stent is a safe and effective option for treating complex coronary blockages, improving outcomes for patients with challenging heart disease.
What could go wrong
This is an observational registry, not a randomized trial, so results may be less definitive. The study is not yet recruiting, and real-world outcomes may vary. Risks include typical stent complications like blood clots or re-narrowing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CALCIFIC CORONARY ARTERIOSCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder coronary atherosclerosis coronary stenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CALCIFIC CORONARY ARTERIOSCLEROSIS COMPLEX CORONARY LESIONS CORONARY ARTERY DISEASE (CAD) MULTIVESSEL CORONARY ARTERY DISEASE SMALL VESSEL ISCHEMIC DISEASE STENOSIS CORONARY

Contacts and locations

Locations

  • Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS)

    Porto Alegre, Rio Grande do Sul, 90610000, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.